1h Free Analyst Time
The global myocardial infarction (mi) therapeutics market is forecasted to grow by USD 2.31 billion during 2025-2030, accelerating at a CAGR of 4.9% during the forecast period. The report on the global myocardial infarction (mi) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of cardiovascular diseases and increasing incidence of myocardial infarction, advancements in drug development and innovation in mi treatment protocols, expanding healthcare infrastructure and improved access to cardiac care.
The study identifies the growing integration of precision medicine in mi treatment strategies as one of the prime reasons driving the global myocardial infarction (mi) therapeutics market growth during the next few years. Also, expansion of combination therapy approaches for secondary prevention and rising emphasis on post-acute care and long-term disease management will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global myocardial infarction (mi) therapeutics market is segmented as below:
By Product
- Antithrombotics
- Vasodilators
- Thrombolytics
- Others
By End-User
- Hospitals
- Specialty clinics and ASCs
- Others
By Route Of Administration
- Oral
- Injectable
By Region
- North America
- Asia
- Europe
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global myocardial infarction (mi) therapeutics market sizing
- Global myocardial infarction (mi) therapeutics market forecast
- Global myocardial infarction (mi) therapeutics market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by End-user
10 Market Segmentation by Route of Administration
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global myocardial infarction (mi) therapeutics market: Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Johnson and Johnson Services, Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., Sanofi SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing integration of precision medicine in mi treatment strategies."
According to the report, one of the major drivers for this market is the rising global burden of cardiovascular diseases and increasing incidence of myocardial infarction.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol Myers Squibb Co.
- CeleCor Therapeutics
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Faraday Pharmaceuticals
- Idorsia Pharmaceuticals Ltd.
- Johnson and Johnson Services
- Merck and Co. Inc.
- Mesoblast Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
